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Background
Peripheral neuropathy is a common adverse event in
patients treated with chemotherapy. The development of
peripheral neuropathy observed in chemotherapy is simi-
lar to the diabetic patients where there is reduction of the
expression and transport of Neural Growth Factor (NGF).
Retinoic acid (RA) regulates genes related to cellular pro-
liferation and the expression of NGF. Phase 1 and in vitro
studies suggested that retinoic acid may synergize the ther-
apeutic effect of chemotherapy, in particular paclitaxel
and cisplatin. We conducted a phase II randomized dou-
ble blind clinical trial to determine the effect of all-trans
retinoic acid on the development of chemotherapy
induced neuropathy based on the combination of paclit-
axel and cisplatin in patients with advanced lung cancer;
in addition we analyzed the therapeutic effect of retinoic
with chemotherapy.
Methods
Thirty four patients with advanced Non Small Cell Lung
Cancer (NSCLC) were included in this study to receive
chemotherapy based on the combination of paclitaxel
175 mg/m2 and cisplatin 80 mg/m2 every three weeks.
The patients' characteristics were median age of 58.9 ± 12
years in the control group and 58.4 ± 12 in the RA (p =
0.914). Prior to chemotherapy and after two cycles of
treatment neurophysiology studies, clinical examination
and serum NGF levels were performed. The patients were
randomized to receive all-trans retinoic acid 20 mg/day or
placebo 1 week before treatment and after completing 2
cycles.
Results
Grade I and II neuropathy was increased in the control
group after 2 cycles (2C) of chemotherapy (66% vs.
24.1% p = 0.05). NFG serum levels were lower in the pla-
cebo group 4.89 pg/ml baseline and 4.6 pg/ml 2C (p =
0.007) vs. all-trans retinoic acid 4.8 pg/ml and 4.7 pg/ml
(p = 0.107). The electrophysiological studies showed that
the placebo group had a greater degree of motor axonal
damage in the median and tibial nerves. The secondary
objective we analyzed response to therapy with differ-
ences in response (complete and partial) of 68.4% in the
retinoic acid group vs 26.6% in the placebo group (RR =
2.6; 95% CI, 1.1 to 6.2; p = 0.016). The disease free sur-
vival in the experimental arm was 10.7 ± 5 vs. 5.1 ± 0.8
months.
Conclusion
All trans retinoic acid has a neuroprotector effect in
patients treated with chemotherapy based on paclitaxel
and cisplatin and has activity in global response and in
time to disease progression.
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